Tirzepatide During Ramadan in People With Obesity Without Diabetes: A Critical Knowledge Gap
Monjur MR
Summary
This letter highlights the absence of clinical data on tirzepatide use during Ramadan fasting in patients with obesity without diabetes. Given that tirzepatide's once-weekly dosing, delayed gastric emptying effects, and appetite suppression may interact unpredictably with prolonged fasting periods, the author calls for dedicated pharmacokinetic and safety studies during religious fasting.
Clinical Significance
With over 1.8 billion Muslims worldwide and rising tirzepatide prescriptions for obesity, clinicians currently lack evidence-based guidance for managing this medication during Ramadan. This represents a real-world dosing concern that could affect medication adherence, glycemic safety in non-diabetic patients, and dehydration risk during extended fasting windows.
Relatert forskning
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: SURPASS-CVOT
In a post hoc analysis of the landmark SURPASS-CVOT trial (n=13,165), tirzepatide demonstrated a 16%…
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: TOGETHER-PsA Trial
In the TOGETHER-PsA trial (n=271), combining tirzepatide with ixekizumab achieved ACR50 + ≥10% weigh…
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss i…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…